于出售事项后，乐普医疗将继续持有2.6886亿股股份，包括由乐普医疗直接持有的2.6606亿股股份及由 乐普医疗的附属公司北京天地和协科技有限公司持有的280万股股份，占公司于公告日期已发行股本约 77.54%，彰显其对公司的坚定信心。公告强调，乐普医疗对集团的业务运营充满信心，出售事项旨在 提升公司股票的流动性。 智通财经APP获悉，心泰医疗(02291)跌超10%，截至发稿，跌10.78%，报24.5港元，成交额2.83亿港 元。 消息面上，心泰医疗今早公告，董事会已获公司其中一名控股股东乐普(北京)医疗器械股份有限公司(乐 普医疗，其股份于深圳证券交易所创业板上市，证券代码：300003)告知，乐普医疗于8月26日通过大宗 交易出售合共1114万股公司H股，每股价格为22.79港元，占公司于公告日期已发行股份总数的约3.21% (出售事项)。 ...

Core Viewpoint - The stock of HeartTech Medical (02291) has dropped over 10%, currently trading at 24.5 HKD, with a transaction volume of 283 million HKD due to a significant share sale by a major shareholder, Lepu Medical [1] Group 1: Shareholder Activity - Lepu Medical announced the sale of a total of 11.14 million H-shares of HeartTech Medical at a price of 22.79 HKD per share, representing approximately 3.21% of the total issued shares as of the announcement date [1] - After the sale, Lepu Medical will continue to hold 268.86 million shares, which includes 266.06 million shares directly held and 2.8 million shares held by its subsidiary, accounting for about 77.54% of the total issued share capital as of the announcement date [1] Group 2: Company Confidence - The announcement emphasized Lepu Medical's strong confidence in the operational performance of HeartTech Medical, stating that the sale was aimed at enhancing the liquidity of the company's stock [1]

Core Viewpoint - The announcement from HeartTech Medical (02291) indicates that its major shareholder, Lepu Medical (300003), will sell 11.14 million H-shares at a price of HKD 22.79 per share, representing approximately 3.21% of the total issued shares, to enhance liquidity while maintaining a significant ownership stake of 77.54% in the company [1] Group 1 - HeartTech Medical's board has been informed by Lepu Medical about the sale of shares [1] - The sale involves 11.14 million H-shares at a price of HKD 22.79 each [1] - Post-sale, Lepu Medical will hold 268.86 million shares, which includes direct and subsidiary holdings [1] Group 2 - The sale is aimed at improving the liquidity of HeartTech Medical's stock [1] - Lepu Medical expresses strong confidence in the business operations of HeartTech Medical [1] - The ownership stake of Lepu Medical after the sale will be approximately 77.54% of the total issued shares [1]

Core Viewpoint - The announcement from HeartTech Medical (02291) indicates that its major shareholder, Lepu Medical (listed on Shenzhen Stock Exchange, stock code: 300003), will sell a total of 11.14 million H-shares at a price of HKD 22.79 per share, representing approximately 3.21% of the total issued shares as of the announcement date [1] Group 1 - Lepu Medical will continue to hold 268.86 million shares post-sale, which includes 266.06 million shares directly held and 2.8 million shares held by its subsidiary, accounting for about 77.54% of the total issued share capital as of the announcement date [1] - The sale is intended to enhance the liquidity of HeartTech Medical's stock, reflecting Lepu Medical's confidence in the company's business operations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2291） 內幕消息 本公司控股股東減持股份 本公告乃由樂普心泰醫療科技（上海）股份有限公司（「本公司」，連同其附屬公 司，「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條及《證券及期貨條例》（香港法例第571章）第XIVA部所訂明的內幕 消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）已獲本公司其中一名控股股東（定義見上市規 則）樂普（北京）醫療器械股份有限公司（「樂普醫療」，其股份於深圳證券交易所創 業板上市，證券代碼：300003）告知，樂普醫療於2025年8月26日通過大宗交易出 售合共11,140,000股本公司H股，每 ...

Core Viewpoint - HeartTech Medical (02291) reported strong mid-term performance with a revenue of 330 million RMB, representing a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million RMB, up 29.8% [1] Company Performance - The company’s basic earnings per share reached 0.5249 RMB [1] - As of the announcement date, HeartTech Medical has a total of 30 products in the market, including occluders, heart valves, and accessories, with 4 products under registration review and 28 products in various stages of research and development [1] Product Pipeline and Market Position - According to CITIC Securities, HeartTech Medical has a comprehensive layout in the structural heart disease sector, covering products for congenital heart disease occluders, cardioembolic stroke, valves, and heart failure [1] - The company has a rich pipeline in the valve sector, with TAVR products already approved for market [1] - In the aortic and peripheral occluder fields, the company is developing biodegradable aortic occluders [1] Growth Drivers and Future Potential - The company has maintained rapid growth in recent years, primarily driven by the market expansion of new products such as biodegradable occluders [1] - HeartTech Medical's biodegradable occluder technology is at a leading level globally, with independent intellectual property rights [1] - There is potential for strong overseas license-out opportunities for this product series, considering the high costs of overseas clinical research and the company's technological advantages [1]

Core Viewpoint - HeartTech Medical (02291) reported strong mid-term performance with a revenue of 330 million RMB, reflecting a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million RMB, up 29.8% [1] Financial Performance - Revenue reached 330 million RMB, representing a 32.4% increase year-on-year [1] - Net profit attributable to shareholders was 182 million RMB, showing a growth of 29.8% [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Portfolio - The company has a total of 30 marketed products including occluders, heart valves, and accessories [1] - There are 4 products under registration review and preparation, with an additional 28 products in various stages of research and development [1] Market Position and Growth Potential - CITIC Securities highlighted HeartTech Medical's comprehensive layout in the structural heart disease sector, covering areas such as congenital heart disease occluders, stroke, valves, and heart failure [1] - The company has a rich pipeline in the valve sector, with TAVR products already approved for market [1] - HeartTech Medical is positioned in the biodegradable aortic occluder market, which is expected to have strong overseas licensing potential due to its leading technology and proprietary intellectual property [1]

公告称，先天性心脏病封堵器产品的销售收入是集团收入的重要组成部分，由截至2024年6月30日止六 个月的1.29亿元增加24.9%至截至2025年6月30日止六个月的1.61亿元，分别占集团同期收入的51.6%及 48.7%。先天性心脏病封堵器产品的销售收入能够实现较快增长，主要由于集团的传统金属封堵器产品 收入稳健增长的同时，集团的第四代MemoSorb生物可降解室间隔封堵器和房间隔缺损封堵器顺利获证 并快速实现商业化后，带来了可观的增量收入，同时集团也正在通过可降解技术实现产品迭代和产品差 异化竞争格局。 心泰医疗(02291)发布截至2025年6月30日止六个月的中期业绩，营业总收入3.3亿元(人民币，下同)，同 比增加32.36%;归母净利润1.82亿元，同比增加29.81%;每股基本盈利0.5249元。 ...

公告称，先天性心脏病封堵器产品的销售收入是集团收入的重要组成部分，由截至2024年6月30日止六 个月的1.29亿元增加24.9%至截至2025年6月30日止六个月的1.61亿元，分别占集团同期收入的51.6%及 48.7%。先天性心脏病封堵器产品的销售收入能够实现较快增长，主要由于集团的传统金属封堵器产品 收入稳健增长的同时，集团的第四代MemoSorb®生物可降解室间隔封堵器和房间隔缺损封堵器顺利获 证并快速实现商业化后，带来了可观的增量收入，同时集团也正在通过可降解技术实现产品迭代和产品 差异化竞争格局。 智通财经APP讯，心泰医疗(02291)发布截至2025年6月30日止六个月的中期业绩，营业总收入3.3亿元 (人民币，下同)，同比增加32.36%;归母净利润1.82亿元，同比增加29.81%;每股基本盈利0.5249元。 ...

Core Viewpoint - The company reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its operations within the cardiac medical device sector [1]. Financial Performance - Revenue increased by 32.4% year-on-year to RMB 330 million [1] - Net profit attributable to shareholders rose by 29.8% year-on-year to RMB 182 million [1] - Basic earnings per share were reported at RMB 0.5249 [1] - The board of directors did not recommend the payment of an interim dividend for the six months ending June 30, 2025 [1] Business Focus and Strategy - The company has over 20 years of experience in the development, production, and commercialization of cardiac medical intervention devices [1] - It is successfully implementing the biodegradability of medical devices and exploring advanced fields such as cardiac valves, mechanical circulatory support, and atrial septal puncture [1] - As a leader in China's interventional medical device industry, the company aims to provide safe, efficient, innovative, and comprehensive medical solutions [1] Product Portfolio - The company currently has 30 products in the market, including occluders, cardiac valves, and accessories [1] - There are 4 products undergoing registration review and preparation [1] - An additional 28 products are in various stages of research and development, including occluders, cardiac valves, surgical accessories, and mechanical circulatory support devices [1]